Signaling Pathway News and Research

RSS

Cause of uveal melanoma discovered, most common eye cancer

A University of British Columbia geneticist has discovered a gene mutation that can cause the most common eye cancer - uveal melanoma.

10 Dec 2008

Cellular 'brakes' may slow memory process in aging brains

University of Florida researchers may have discovered why some brain cells necessary for healthy memory can survive old age or disease, while similar cells hardly a hairsbreadth away die.

10 Dec 2008

Brain deletion of FK506-binding protein enhances repetitive behaviors in mice

A new study reveals a link between dysregulation of a common signaling pathway and repetitive behaviors similar to those associated with multiple neurological and neurodegenerative disorders including, autism spectrum disorders, obsessive compulsive disorder, schizophrenia, and Huntington's disease.

10 Dec 2008

Genetic signature may lead to better treatments for pediatric liver cancers

Scientists have identified a genetic signature that is remarkably effective at predicting the prognosis of an aggressive liver cancer in children.

8 Dec 2008

Genetic breakdown in Fanconi anemia may have link to HPV-associated cancer

A genetic malfunction that causes DNA instability in people with the blood disorder Fanconi anemia may put them at high risk for squamous cell carcinomas linked to human papillomavirus (HPV), according to a study posted online ahead of print by Oncogene.

3 Dec 2008

Advance in K-Ras-mutated cancer research

A team of cancer researchers from several Boston academic medical centers has discovered a potential treatment for a group of tumors that have resisted previous targeted therapy approaches.

30 Nov 2008

Medarex starts phase 1b clinical trial with MDX-1106 for the treatment of cancer

Medarex, Inc. has announced it has initiated a Phase 1b clinical trial for MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody for the treatment of cancer.

24 Nov 2008

New insight into the response of human skin to radiation

Scientists have new insight into the response of human skin to radiation and what drives the most aggressive and deadly form of skin cancer.

20 Nov 2008

REOLYSIN shown to benefit some sarcoma patients

New data shows that some sarcoma patients are benefiting from treatment with REOLYSIN, developed from a harmless virus called the reovirus that most people are exposed to at some point in their lives.

19 Nov 2008

New molecular insight into vertebrate brain development

In the December 1st issue of G&D, Dr. Fred H. Gage (The Salk Institute for Biological Studies) and colleagues reveal a role for the Hippo signaling pathway in the regulation of vertebrate neural development, identifying new factors - and potential therapeutic targets - that may be involved in congenital brain size disorders and neurological tumor formation.

17 Nov 2008

New research sheds light on key trigger of embryonic stem cell differentiation

Clusters of mouse embryonic stem cells called embryoid bodies more closely approximate true embryos in organization and structure than previously thought, according to researchers at the Stanford University School of Medicine.

6 Nov 2008

New therapeutic target for inflammatory disorders

Researchers at Hospital for Special Surgery have identified a potential new therapeutic target that could be used to treat inflammatory disorders, such as rheumatoid arthritis.

6 Nov 2008

Human papillomavirus helps cervical and head and neck cancers resist treatment and grow and spread

The human papillomavirus (HPV) allows infected cervical and head and neck cancer cells to maintain internal molecular conditions that make the cancers resistant to therapy and more likely to grow and spread, resulting in a poor prognosis for patients, researchers with UCLA's Jonsson Cancer Center found.

4 Nov 2008

YM Biosciences reports on early trials of nimotuzumab in brain metastases and high-grade glioma

YM BioSciences Inc. has announced data from two clinical trials of nimotuzumab, its humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Preliminary results from the two trials which are evaluating nimotuzumab in combination with radiation therapy for the treatment of brain metastases and high-grade gliomas, conducted by YM's licensor, were presented at the 2008 EORTC-NCI-AACR annual meeting recently held in Geneva, Switzerland.

3 Nov 2008

Exercise-induced fatigue in muscular dystrophies, study points to potential new therapies

A University of Iowa study suggests that the prolonged fatigue after mild exercise that occurs in people with many forms of muscular dystrophy is distinct from the inherent muscle weakness caused by the disease.

26 Oct 2008

Beyond recognizing odors, a single neuron controls reactions

Babies will smile when they catch the scent of vanilla, but a whiff of rotting meat will send them into fits. From people to mice and flies to worms, animals of all kinds are born with likes and dislikes thanks to the evolutionary wisdom collected in their genes. But new research shows that some preferences are still surprisingly flexible at even the most basic level - that of the sensory neuron itself - and that our nervous system may be even more adaptable than we thought.

20 Oct 2008

Oxidative stress: mechanism of cell death clarified

Dr. Marcus Conrad of the Institute of Clinical Molecular Biology and Tumor Genetics at the Helmholtz Zentrum Munchen has decrypted the molecular mechanism through which the death of cells is caused by oxidative stress.

3 Sep 2008

Atomic bomb's effect results in adult-onset thyroid cancer

Radiation from the atomic bomb blasts in Hiroshima and Nagasaki, Japan, in 1945, likely rearranged chromosomes in some survivors who later developed papillary thyroid cancer as adults, according to Japanese researchers.

1 Sep 2008

Rifamycin antibiotics attack tuberculosis bacteria with walls, not signals

Amid concerns about the rising number of new tuberculosis cases worldwide, researchers led by Rockefeller University's Seth A. Darst have reexamined and disproved a theory that describes how a potent class of antibiotics kills a deadly form of bacteria. The findings, which will appear in this week's online issue of the Proceedings of the National Academy of Sciences, not only bring scientists closer to understanding how these antibiotics work but also how the bacteria become resistant to their effects.

19 Aug 2008

Medulloblastoma originates in normal brain "stem" cells that turn malignant

An aggressive childhood brain tumor known as medulloblastoma originates in normal brain "stem" cells that turn malignant when acted on by a known mutant, cancer-causing oncogene, say researchers from Dana-Farber Cancer Institute and the University of California, San Francisco (UCSF).

11 Aug 2008